Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry

Abstract Background Prior work showed that patients from the CorEvitas Psoriasis Registry who had previously failed a prior biologic and then initiated ixekizumab demonstrated improvements in disease severity and patient-reported outcomes after 6 months. However, newer therapies such as interleukin-...

詳細記述

保存先:
書誌詳細
主要な著者: Mark Lebwohl (著者), Bruce Strober (著者), Amy Schrader (著者), Alvin H. Li (著者), Thomas Eckmann (著者), Baojin Zhu (著者), William N. Malatestinic (著者), Julie Birt (著者), Meghan Feely (著者), Andrew Blauvelt (著者)
フォーマット: 図書
出版事項: Adis, Springer Healthcare, 2024-06-01T00:00:00Z.
主題:
オンライン・アクセス:Connect to this object online.
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

インターネット

Connect to this object online.

3rd Floor Main Library

予約・返却請求 3rd Floor Main Library
請求記号: A1234.567
所蔵 1 利用可